U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 5 of 5 results

Status:
US Approved Rx (2018)
First approved in 2000

Class (Stereo):
CHEMICAL (EPIMERIC)

Targets:


Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine. Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic ac...
Status:
US Approved Rx (2019)
First approved in 2000

Class:
PROTEIN

Targets:

Conditions:

Bivalirudin is a synthetic 20 amino acid peptide rationally designed based on structural studies of hirudin, a naturally occurring anticoagulant. Bivalirudin is sold under the brand name Angiomax and is indicated for use as an anticoagulant in patien...
Status:
US Previously Marketed
First approved in 2003

Class:
PROTEIN


Desirudin (Iprivask), a recombinant hirudin, is a parenteral direct thrombin inhibitor approved to prevent venous thromboembolism in patients undergoing elective hip replacement surgery. Desirudin is a potent inhibitor of both clot-bound and freely c...
Status:
US Previously Marketed
First approved in 1998

Class:
PROTEIN


Lepirudin is a direct thrombin inhibitor obtained by recombinant technology from the medicinal leech and used for treatment of heparin-induced thrombocytopenia (HIT). Lepirudin was the first direct thrombin inhibitor approved and most frequently used...
Status:
US Approved Rx (2018)
First approved in 2000

Class (Stereo):
CHEMICAL (EPIMERIC)

Targets:


Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine. Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic ac...